FDA Approves Vaccine for Meningococcal Disease in Adolescents
Pfizer’s PENBRAYA, a vaccine for meningococcal groups A, B, C, W and Y, has been approved by the U.S. Food and Drug Administration (FDA).
Fourth Dose of COVID-19 Vaccine Increases Protection in Rheumatic Disease Patients
A new study suggests that patients receiving disease-modifying antirheumatic drugs should receive a fourth dose of the mRNA vaccine to protect against COVID-19.
First Vaccine for Mosquito-Born Viral Disease Is Approved by FDA
The U.S. Food and Drug Administration has approved IXCHIQ, Valneva’s single-dose, live-attenuated vaccine indicated for the prevention of disease caused by chikungunya virus in individuals 18 years of age and older who are at increased risk of exposure to CHIKV.
New Vaccine Could Fight Hospital-Acquired Infections by Boosting the Immune System
A new type of vaccine could stimulate the innate immune system to prevent deaths from hospital-acquired infections (HAIs) caused by a variety of bacteria and fungi, according to a recent study.
Study Shows Positive Results for mRNA-Based Combination Influenza and COVID-19 Vaccine
A Phase I/II study evaluating the safety, tolerability and immunogenicity of Pfizer and BioNTech’s mRNA-based combination vaccine candidates for influenza and COVID-19 among healthy adults 18 to 64 years of age show positive topline results.
Intranasal COVID-19 Vaccine Shows High Seroresponse
A Phase I randomized, double-blind, placebo-controlled dose-escalation study in healthy adults, called CDX-CoV-001, has found Codagenix’s intranasal COVID-19 vaccine candidate, CoviLiv, showed the vaccine had a high seroresponse rate and induced mucosal immunity in volunteers not previously vaccinated or infected.
Moderna’s Influenza-COVID-19 Vaccine Demonstrates Immunogenecity
Results from Moderna’s Phase I/II clinical trial that evaluated the safety and immunogenicity of its influenza-COVID-19 vaccine, mRNA 1083, showed immunogenicity against all four influenza strains compared to a standard dose of the influenza vaccine, Fluarix, in adults 50 to 64 years of age and against an enhanced influenza vaccine, Fluzone HD, in adults 65 to 79 years of age.
Just Arrived: A Trio of Active and Passive Vaccines Against RSV
For decades, respiratory syncytial virus (RSV) has defied the best efforts of vaccine makers to bring it to heel, until now.
Merck’s Ebola Vaccine Approved for the Pediatric Population
An expanded indication for ERVECO for the prevention of disease caused by Zaire ebolavirus in individuals 12 months of age and older has been approved by the U.S. Food and Drug Administration.
Study Finds Adult Vaccines Potentially Protect Against Alzheimer’s
A new study conducted at the University of Texas Health Science Center at Houston found that people who received shingles and pneumonia vaccines — along with tetanus and diphtheria — had as much as a 30 percent reduced risk of developing Alzheimer’s the most common type of dementia.